NCT02988921View on ClinicalTrials.gov

MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy

NARecruitingINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

January 31, 2025

Study Completion Date

December 31, 2026

Conditions

Esophagus CancerEsophagogastric Junction Cancer

Interventions

DEVICE

MRI and CT

RADIATION

Ratiotherapy

DRUG

Paclitaxel, platinum-based drug

Trial Locations (1)

100021

RECRUITING

Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing

All Listed Sponsors

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

NCT02988921 - MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy | Biotech Hunter | Biotech Hunter